Description of treatment management of patients with Major Depressive Disorder and inadequate response - MADDRE
Study identifier:NIS-NGR-XXX-2011/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A cross-sectional observational study to describe treatment management of patients with Major Depressive Disorder (MDD) and inadequate response to antidepressants in Greece
Medical condition
Major depressive disorder
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
All
Actual Enrollment
545
Study type
Observational
Age
N/A
Date
Study Start Date: 01 Sept 2011
Primary Completion Date: 01 Mar 2012
Study Completion Date: 01 Mar 2012
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Group 1 Inpatients and outpatients diagnosed with major depressive disorder as per the DSM-IV criteria who had poor disease control during antidepressant treatment and have completed 4 weeks of add-on drug therapy at enrolment in the study. The percentage of patients with CGI-I score ≤ 2 at study Visit (4 weeks after the commencement of add-on treatment). | - |
Contacts
Investigators
Principal Investigator
Panagiotis Pontikis
Marketing Company Medical and Regulatory Affairs Director, AstraZeneca S.A. Greece
